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Abstract
Background: The atrial appendages are a tissue reservoir for cardiac stem cells. During on-pump coronary artery
bypass graft (CABG) surgery, part of the right atrial appendage can be excised upon insertion of the right atrial
cannula of the heart-lung machine. In the operating room, the removed tissue can be easily cut into micrografts for
transplantation. This trial aims to assess the safety and feasibility of epicardial transplantation of atrial appendage
micrografts in patients undergoing CABG surgery.
Methods/design: Autologous cardiac micrografts are made from leftover right atrial appendage during CABG of 6
patients. Atrial appendage is mechanically processed to micrografts consisting of atrial appendage-derived cells
(AADCs) and their extracellular matrix (ECM). The micrografts are epicardially transplanted in a fibrin gel and covered
with a tissue-engineered ECM sheet. Parameters including echocardiography—reflecting cardiac insufficiency—are
studied pre- and post-operatively as well as at 3 and 6 months of the follow-up. Cardiac functional magnetic
resonance imaging is performed preoperatively and at 6-month follow-up. The primary outcome measures are patient
safety in terms of hemodynamic and cardiac function over time and feasibility of therapy administration in a clinical
setting. Secondary outcome measures are left ventricular wall thickness, change in the amount of myocardial scar
tissue, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels, New York Heart Association class, days in hospital, and changes in the quality of life. Twenty
patients undergoing routine CAGB surgery will be recruited to serve as a control group.
Discussion: This study aims to address the surgical feasibility and patient safety of epicardially delivered atrial
appendage micrografts during CABG surgery. Delivery of autologous micrografts and AADCs has potential applications
for cell and cell-based gene therapies.
Trial registration: ClinicalTrials.gov Identifier: NCT02672163. Date of registration: 02.02.2016
Keywords: Autologous micrografts, Heart failure, Coronary artery bypass surgery, Cell therapy, Atrial appendage,
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Background
Loss of functional myocardium after, for example, an is-
chemic insult instigates a need for the remaining tissue
to undergo various levels of remodeling to compensate
for the declining pumping efficacy. Dead tissue is
replaced by non-contractile fibrous scar, while hyper-
trophy and dilatation may be prominent in other parts
of the myocardium struggling to compensate for the lost
pumping function. Despite improved drug therapies,
many patients develop heart failure over time [1]. The
prognosis of heart failure is poor; 4-year survival is less
than 50%, and 40% of patients are dead or readmitted to
hospital within the first year [2, 3]. Long-term survival
has increased due to revascularization techniques such as
coronary artery bypass grafting (CABG). Unfortunately,
25–30% of the operated patients do not respond to
revascularization surgery by improved perfusion. These
patients are thus in much higher risk of heart failure and
death [4]. Economically, heart disease exerts a severe
burden worldwide that is accentuated with population
aging. In 2010, for example, heart disease cost the USA
$316 billion [5].
During the last decade, cell-based therapies have
entered the clinic with a new hope as therapy for
heart failure. Several cell transplantation strategies
have been evaluated in experimental as well as in
clinical trials [6-8]. Consistent improvement in cardiac
function has been reported in studies that have used
cells of cardiac origin as the therapeutic cell popula-
tion [9, 10]. Moreover, when patient’s autologous cells
are used, the immune system is not activated to reject
the cells, which are thus retained longer after trans-
plantation. It has also been shown that enhancing
vascular supply of nutrients together with cellular ad-
herence to extracellular substrata further promotes
the survival of transplanted cells [11].
In conjunction with revascularization surgery, the aim
for cell therapy is to improve the functional recovery of
the myocardial scar by restoring the cellular loss of the
infarcted area. The cells for therapy need to be able to
give rise to all structures of the myocardium. In
principle, this means that the therapeutic cells must be
capable of forming cardiac muscle (cardiomyocytes),
supporting extracellular matrix (fibroblasts) and vascula-
ture (endothelial and smooth muscle cells).
Cardiac-derived stem cells have higher potential to
develop along cardiac lineage [7] and differentiate into
cardiac myocytes [12] in vivo than the cells derived from
other organs. Cardiac stem cells are self-renewing and
multipotent, and they have high capacity to form clones
and also enhance the differentiation of other progenitor
cells to e.g. endothelial and smooth muscle cells. At least
six types of stem cells have been isolated and character-
ized from the heart: Sca-1 cells [13], c-kit cells [14], islet-1
cells [15], cardiac side population cells [16], cardiosphere-
derived cells [17], and ALDH(+) (aldehyde dehydrogenase)
cells [18]. Cardiac stem cells can be found in abundance
in the right atrial appendage [18, 19, 20] which thus repre-
sents an appealing source of tissue for cell therapy use.
The efficacy of cell therapy is decreased by the high
rate of cell apoptosis soon after the transplantation.
Numerous studies have focused on the different routes
of the cell delivery. The most investigated approaches
are intracoronary and intramyocardial injections and
epicardial delivery. Animal models have proven the epi-
cardial delivery to have advantages in securing adequate
cell engraftment when compared to any kind of cell in-
jections [21, 22].
Overall, cell-based therapies (by any delivery route)
are regarded as safe to the patients [23]. For example,
they have been shown to improve left ventricular func-
tion [23–26], quality of life, and physical activity toler-
ance [23, 25, 27]. However, further evidence on safety
and feasibility of the epicardial delivery of cardiac stem
cells is required.
The primary objective of this trial is to evaluate the
clinical feasibility of intraoperative harvesting, process-
ing, and transplantation of autologous atrial appendage
tissue micrografts in terms of success in completing the
delivery of the transplant to the myocardium in conjunc-
tion with cardiac surgery in the operating room as well
as in terms of time restrictions associated with both
transplant processing and cardiac surgery. Our primary
objectives, in terms of safety, are to evaluate acute and
6-month cardiovascular parameters including rhythm,
cardiac function, and need for vasoactive or inotropic
medication. Our secondary objective is to obtain an ini-
tial insight into the therapeutic effect of atrial appendix
micrograft transplantation as measured by baseline and
6-month follow-up cardiac functional MRI.
Methods/design
Patient selection
In all, 26 patients from the Helsinki University Hospital,
Finland, will be recruited to the study in chronological
order by the head researcher. Similar to our previous
clinical cell therapy trial [28–31], patients of either
gender will be initially evaluated for participation by the
cardiologists. Patients with heart failure and scheduled
for elective CABG are considered eligible for participa-
tion in the trial if they meet the inclusion criteria. The
criteria for inclusion and exclusion of the patients are
presented in Table 1. The first six patients will be
recruited to the atrial appendage-derived cell (AADC)
arm. Each patient is given both oral and written infor-
mation about the trial, and the patient’s written in-
formed consent is required for participation and
obtained by the head researcher. After scheduling to
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surgery, patients will undergo a period of at least 4 to
8 weeks for optimization of drug therapy while waiting
for the elective operation.
Echocardiography (ECHO), quality of life (QoL) ques-
tionnaire (standardized SF-36 health survey question-
naire), New York Heart Association (NYHA) class, basic
laboratory tests, and N-terminal pro-B-type natriuretic
peptide (NT-proBNP) from blood are all evaluated at
baseline as well as at 3 and 6 months of the follow-up.
Blood RNA and EDTA plasma samples are taken at the
pretrial and at 6 months of the follow-up to search
markers for prognostic factors. Cardiac MRI is per-
formed at the pretrial and at 6 months of the follow-up.
To determine the safety of the procedure, the next 20
patients who meet the same inclusion and exclusion cri-
teria and are scheduled for elective CABG operation are
recruited to the study as control patients. These patients
are treated according to the normal hospital protocol,
without the extracellular matrix (ECM) sheet and any
additional imaging, examination, or blood tests required
for the AADC therapy group. Written consent is ob-
tained also from the control patients.
Cell isolation
During CABG surgery, autologous cardiac cells are har-
vested from a leftover right atrial appendage tissue that
is removed for insertion of the heart-and-lung machine.
This material serves a safely removable source for car-
diac cells. However, quality of the tissue varies greatly
between the patients: atrial fibrillation and dilatation as
well as diabetes mellitus and obesity may cause accumu-
lation of connective and adipose tissue [32–34], which
decrease the quality of the appendage tissue. Also, the
size of appendage differs between patients according to
age and gender. To standardize the amount of tissue re-
moved for harvesting, the size of removable appendage
is 5 × 10 mm and the weight from 600 to 800 mg. The
harvested tissue is processed on site in the operating
room using a cell therapy tissue homogenizer (Rigenera
System, HBW s.r.l., Turin, Italy) (Fig. 1a (A)) [35]. The
device is CE-marked and in clinical use for isolation of
therapeutic cells from a skin biopsy to treat hard-to-heal
or chronic wounds. This system enables extraction of 5–
10 millions of single cells per gram of atrial appendage
tissue. In addition to these single cells that can be
counted, the mixture contains a vast number of cell
clusters, i.e., micrografts containing many intercon-
nected cells attached to their extracellular matrix, raising
the estimated cell number to reach at least 60 million vi-
able cells per gram of tissue. The isolation of the cells
can be performed with ease and strict adherence to ster-
ility in the operating room by a nurse who has received
basic training in using the instruments. Initial training
was carried out in a cell culture laboratory, and the
protocol to accompany CABG surgery was further
trained in a large animal model. This cell isolation tech-
nology is a straightforward approach for administering
autologous cell therapy in a routine and safe manner
during surgical procedures. The system utilizes a sterile,
single-use tissue homogenizer surface to generate the
micrografts.
The isolated AADC micrografts are applied in within
cardioplegia suspension as a composite graft on the
damaged myocardium using the epicardial transplant-
ation technique. Firstly, the suspension of autologous,
freshly isolated AADCs are applied onto the extracellular
matrix sheet (Cormatrix® ECM™ Technology, Cormatrix
Cardiovascular Inc., Atlanta, GA, USA). Fibrin sealant
(Tisseel™, Baxter Healthcare Corp. Westlake Village, CA,
USA), routinely used in surgery for hemostasis and tis-
sue sealing, will be added into the cell suspension in
order to secure the adherence of the suspension to the
matrix (Fig. 1a (B)). Then, the matrix sheet is placed on
top of the damaged myocardium. Administration of the
transplant is presented in Fig. 1b. The Cormatrix® readily
attaches to the tissue but will be further secured to the
myocardial surface by suturing (Fig. 1a (C)).
Therapy administration
A standard CABG operation is performed under
cardiopulmonary bypass and mild hypothermia. The
operations take place under cardiac arrest and cardio-
plegia protection. After completion of the bypass
anastomoses, each patient receives, under cardiac ar-
rest, a Cormatrix® patch containing autologous cells
in physiological saline and fibrin sealant on the in-
farction area. The area of application is selected
Table 1 Inclusion and exclusion criteria for patients enrolled in
the study
Criteria for eligibilty
Inclusion criteria
1 Stable coronary artery disease filling the criteria for bypass surgery
2 Age between 18 and 75 years
3 Informed consent obtained
4 LVEF between ≤ 45 and ≥ 20%
5 NYHA class II–IV heart failure symptoms
Exclusion criteria
1 Heart failure due to LV outflow tract obstruction
2 History of life-threatening ventricular arrhythmias or resuscitation, a
condition possibly repeating, or an implantable cardioverter-
defibrillator
3 Stroke or other disabling condition within 3 months before
screening
4 Severe valve disease or scheduled valve surgery
5 Renal dysfunction (GFR < 84 ml/min/1.73 m)
6 Other disease limiting life expectancy
7 Contraindications for coronary angiogram or MRI
8 Participation in some other clinical trial
LVEF left ventricular ejection fraction, NYHA New York Heart Association, LV left
ventriculum, GFR glomerular filtration rate
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before surgery by using the pre-CABG MRI imaging
data. The therapy application procedure is carefully
photographed during each surgery, and the treatment
administration site is specified in patient documents
for analysis.
Clinical cardiac MRI
Cardiac MRI is performed with a 1.5T Avanto fit scan-
ner and phase array cardiac coil (Siemens, Erlangen,
Germany). Images will be obtained with electrocardiog-
raphy (ECG) gating and during breath-holding. LV struc-
ture and function are imaged by a standardized MRI
protocol [36]. TrueFISP cine series is obtained at the
vertical and horizontal long axes for scout to line up
short-axis images. The stack of short-axis images is ob-
tained from the mitral valve plane through the apex. To
detect the myocardial scar, late gadolinium enhancement
(LGE) is imaged with a 2D-segmented inversion recov-
ery gradient ECHO sequence 12 to 20 min after
Dotarem® (279.3 mg/ml; dose 0.2 mmol/kg) injection.
LGE images are obtained at the same views and slice/
gap thickness as cine imaging.
End-point measures
Table 2 lists the outcome measures of the trial. Specif-
ically, the primary outcome measures are patient
safety in terms of hemodynamic and cardiac function
and feasibility of the therapy administration in a
clinical setting. Hemodynamics is evaluated during
the operation and stay at the intensive care unit
(ICU) by the need for vasoactive medication and suc-
cess of weaning from cardiopulmonary bypass and
respirator. Postoperative hemodynamic criteria for
assessing safety are cardiac index, hemoglobin, SvO2,
serum potassium level, and blood glucose level. Car-
diac function is evaluated also during the operation
by transesophageal ECHO and during the stay at ICU
by transthoracical ECHO as well as telemetric moni-
toring of rhythm. Feasibility is evaluated by the
success in completing the delivery of the cell sheet to
the myocardium, waiting times in minutes for either
the cell sheet or the heart after finishing anastomoses,
and the success in closing the right atrial appendage
by purse string suture without additional sutures or
patching.
ba
A
B
c
Fig. 1 a Preparing the AADC-sheet. (A) The atrial appendage tissue is processed with cell therapy tissue homogenizer (Rigenera-system). (B) The
micrografts are secured to extracellular matrix sheet (Cormatrix®) by using a fibrin sealant (Tisseel™). (C) The AADC sheet is placed to the
myocardium in the location of infarction scar (animal model). b Administration of therapy during CABG surgery. Figure reproduced from our
article by Lampinen et al. (Current Gene Therapy, 2015)
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The secondary outcome measures are change in LV
wall thickness and movement and diastolic function as
measured by MRI, change in the amount of myocardial
scar tissue as measured by MRI, local changes in systolic
and diastolic measures as estimated by ECHO, changes
in left ventricular ejection fraction (LVEF), pro-BNP
level, NYHA class, hospitalization or the days in hos-
pital, and QoL.
Figure 2 presents the timeline of the study indicating
enrollment and follow-up as well as timing of laboratory
tests, MRI, and echocardiographic imaging for each
patient.
Statistical analysis
Statistical methodology as published previously by Pätilä
et al. [28] will be utilized. Briefly, the Mann-Whitney U
test will be used for non-parametric continuous variables
and results will be reported as median with interquar-
tile range (IQR). Categorical variables will be analyzed
using Fisher’s exact test. Intra-observer variability will be
assessed using the Bland-Altman method. Testing for p values
will be carried out two-sided with p< 0.05 considered statisti-
cally significant. Results should be treated as preliminary due
to the small sample size and will be presented with 95%
confidence intervals. A sample size of 26 has been shown to
be sufficient in our previous studies to demonstrate safety.
Computation will be achieved with PASW Statistics (IBM
Inc., Armonk, NY) or equivalent software.
Safety considerations
The patients are monitored, and their cardiac function is
closely evaluated under the hospitalization period. In
case of any abnormalities, the head researcher will be
immediately informed and the study will be halted for
evaluation of the cause. Continuation of the study will
then be further assessed by the head researcher and the
clinical panel responsible for the patient care.
Discussion
The specific aim of the project is to evaluate safety and
feasibility of AADC therapy. Patients enrolled to our
study have decreased cardiac function and remodeled
left ventricle. Therefore, perioperative safety and adverse
effect-free long-term survival are the main concerns re-
garding the planned procedure and follow-up in our
study. The study protocol has been designed keeping
also patient convenience in mind. Appendage tissue is
harvested during cannulation of the right atrium, and
Table 2 Primary and secondary outcome measures
Primary outcome measures Secondary outcome measures
Safety Preliminary efficacy
For assessing hemodynamics during the operation and at the intensive care unit For assessing cardiac function and remodeling as
measured by MRI
1. Need for vasoactive medication 1. Left ventricular wall thickness
2. Cardiac index in l/min/m2 2. Change in the amount of myocardial scar tissue
3. Hemoglobin in g/l 3. Change in left ventricular ejection fraction
4. Oxygen saturation in the pulmonary arterial blood (SvO2) in % 4. Change in movement and diastolic function of left
ventricular wall
5. Serum potassium level in mmol/l Others
6. Blood glucose level in mmol/l 1. Plasma concentrations of N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) levels
For assessing cardiac function during and after the operation by echocardiogram 2. New York Heart Association class
7. Left ventricular ejection fraction (EF) in % 3. Days in hospital
8. Pericardial effusion in mm 4. Changes in the quality of life measured by
questionnaire
For assessing cardiac function after the operation
9. Telemetric monitoring of rhythm
Feasibility
1. Success in completing the delivery of the transplant to the myocardium
2. Waiting time in minutes for the finished transplant to be placed on the
myocardium after doing all the required anastomoses
3. Waiting time in minutes for the heart after doing all the anastomoses and
before the transplant is finished
4. Closing the right atrial appendage after removing the standardized tissue piece
for preparing the transplant
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therefore, no additional procedure is needed. Isolation of
the cells and preparing the matrix for transplantation is
done simultaneously with the CABG operation in the
operating room, so the perfusion time and the aorta
clamp time are not increased. After the bypass anasto-
moses, the AADC sheet is placed on the myocardium
with three to four sutures allowing the myocardium to
contract without interference. Immediately after CABG,
the heart is most likely to develop postoperative ische-
mia due to aorta cross-clamping and following reperfu-
sion. This may change the metabolism of the heart and
influence ability of tissues to adapt to the AADC sheet
placed on the myocardium. Post-operatively, the patients
are closely monitored at the intensive care unit and at
the ward in case for any arrhythmias, infection-related
decrease in cardiac function, or hemodynamic abnor-
malities. After the hospitalization period, the patients
are followed up at 3 and 6 months for any adverse ef-
fects or disturbance in the recovery.
Optimal pharmacotherapy for heart failure and revascular-
ization are crucial, but currently, no medical treatment or
surgery can repair the irreversibly infarcted and failing myo-
cardium. Autologous cell therapy offers a way to replace
dead cardiac tissue with a viable and functional one. Cell
therapies have been demonstrated to be generally safe treat-
ments for heart failure in numerous studies [23, 26, 27].
According to meta-analysis of cell therapy trials, therapies
are associated with minimal major intervention-related ef-
fects and do not increase the incidence of arrhythmias [37].
The review concluded that cell therapy reduced mortality
and re-hospitalization caused by heart failure during long-
term follow-up and improved global LVEF, NYHA functional
class, proBNP levels, and QoL [37]. On the other hand, some
trials reporting results from the myoblast intramyocardial in-
jection have demonstrated increased frequency of arrhyth-
mias compared to epicardial delivery [38–41].
In our previous study, we explored the effects of autolo-
gous intramyocardial bone marrow mononuclear cell
(BMMC) transplantation in ischemic LV dysfunction [32].
The transplantation was done by injecting autologous
BMMCs to the myocardial infarction area intra-
operatively. We found no harmful effects of the treatment
in any clinically relevant parameters (assessing cardiac
function, hemodynamic response, and perioperative myo-
cardial damage) in short- or long-term follow-up [28, 31].
The most important finding in that study was that
the BMMC therapy showed significant decrease in the
size of local scar on MRI [28], which has been proven
to be a major prognostic factor after myocardial in-
farction [42–44]. The biggest challenge with the
method of injecting the cells is the low rate of sus-
tained cells in the graft. This is caused by mechanical
leakage [45], poor vascularization of the infarcted
area, and apoptosis due to loss of cell anchorage
(extracellular matrix) [46]. Compared with the injec-
tions, a number of studies have demonstrated that
epicardial delivery of the therapeutic cells associates
with greater number of retained cells [21] and better
graft functionality [22]. Therefore, epicardial delivery
of cell-seeded micrografts is the primary choice for
Fig. 2 Timeline of the study indicating enrollment and follow-up as well as timing of laboratory tests, MRI, and echocardiographic
imaging modalities
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the delivery route and the approach in our forthcom-
ing study.
The purpose of this study is to address patient safety
and clinical feasibility of the therapy. We will determine
the success of this trial based on the primary outcome
measures. If the therapy is proved to be safe without any
disturbances in patients’ cardiac rhythm, hemodynamics,
and cardiac function and the method can be successfully
performed simultaneously with bypass surgery, the re-
sults of this trial are then further evaluated in succeeding
trials for transplant’s therapeutic efficacy. Double-blind
randomization and placebo control using the matrix
sheet with and without the micrografts will be consid-
ered for our future studies.
Our interests has also been combining stem cell ther-
apy with gene therapy and using autologous minimally
manipulated micrografts in conjunction with CABG sur-
gery [47–49]. By administrating genetically modified
transplanted cells, we are able to repair also faulty gen-
etic tissue of the heart [47]. Even though cell therapy has
promising results, studies regarding safety and clinical
efficacy require further investigation.
This study on feasibility and safety of autologous atrial
micrograft epicardial transplantation has some limita-
tions. The allocation is not randomized, and the patients
are recruited to the groups in chronological order. Also,
this trial is carried out as a one-center trial, and there-
fore, the number of eligible patients is small. Although
randomization does not occur, we have considered that
no selection bias will take place due to low number of
patients and because all patients who are eligible and
give their consent are included in the study.
In conclusion, given the severe problems associated
with heart failure and its increasing high prevalence [50]
in the elderly population, it is of utmost importance to
devise effective novel evidence-based cell therapies. Epi-
cardial delivery of AADCs with ECM cells represents a
novel approach to restore the cellular loss of infarcted
myocardium. We believe that AADC therapy adminis-
tered during CABG surgery will have impact on patient
treatment in the future.
Trial status
Recruitment of the patients started in February 2016.
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